Antengene Announces XPOVIO® Regulatory Approval in Taiwan for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma
XPOVIO® is the first and only exportin 1 (XPO1) inhibitor approved in Taiwan. Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company dedicated to...